Not sure what you are responding to here, given the post has been moderated, but if you're going to dismiss another drug, any drug, at least try to understand it's most basic story first.
The only thing holding Bisantrene (as it is now called) back, was the mechanism of delivery. They could not solve that problem in the 90s. It has been solved in the last year. RC110 and RC220 are essentially the same drug in terms of efficacy, but RC220 can deliver that efficacy to a global market.
I'd suggest you take a close look at Bisantrene's findings in treating multiple cancer types, and it's findings in reducing the cardio-toxicity of the most commonly used chemo drug on the planet (and the implications of that for long term cancer survivors), before you make smug comments.
RAC and IMU are not in competition. One succeeding will not kill the other company off. And to be honest the sniping from both ends is tiresome. This is not to be confused with well researched pressure-testing of either company's performance, which all investors should welcome.
It's still a journey for both companies, and if IMU reaches the destination you're looking for, more power to you! And more importantly, the people it will help.
IMU Price at posting:
1.3¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)